Atomo Diagnostics (ASX:AT1), has put in a purchase order from Viatris Healthcare for HIV self-tests, valued at approximately $570,000.
The tests, branded under Mylan, will be manufactured by Atomo and supplied to several Low and Middle-Income Countries. The orders are scheduled for production in the upcoming months.
The HIV self-tests produced by Atomo under the Mylan brand are designed to provide accessible and reliable testing solutions, particularly in areas around the world where healthcare resources may be limited. By supplying these tests to predominantly third world countries, Atomo aims to help improve healthcare access and outcomes in the developing world.
The partnership between Atomo and Viatris is seen as a means of improving collaboration in addressing global health challenges. Through innovations such as HIV self-tests, Atomo sees itself as making meaningful strides towards advancing medical cures to eradicate HIV, and achieving healthcare equity worldwidd.
AT1 has been trading at 3.2 cents.